Fabrice André, MD, PhD, received his MD in Grenoble in 2002, and a PhD in Biotechnology from Paris University in 2005.
He is a past recipient of Young Investigator and Career Development awards from the American Society of Clinical Oncology (ASCO) and is currently Professor in the Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
His research work in the field of biomarkers and personalised therapies focuses on biomarker discovery, development of targeted agents and implementation of personalised medicine. His team includes 50 people working on basic sciences, bioinformatics, biotechnologies and clinical research. He is also leading phase I-III trials testing targeted agents in the field of breast cancer and large national trials testing implementation of high throughput technologies in the health care system.
Professor André has published more than 200 peer reviewed papers, including papers in the New England Journal of Medicine, Lancet, Nature Medicine, Science, Lancet Oncology and Journal of Clinical Oncology, either as main or co-author.
Professor André is chairman of the biomarker group at UNICANCER (French cooperative group) and was a member of several scientific committees for international meetings, including SABCS, AAACR, ECCO, ESMO, and IMPAKT.
Professor André has been a member of the Annals of Oncology Editorial Board (2010-2013), Associate Editor since 2014 and in September 2017 became Editor-in-Chief.
He has been a member of the ESMO Educational Committee since 2009, he was coordinator (2012-2014) and member (since 2015) of the ESMO Breast Cancer Faculty. Professor André was also a member of the ESMO Cancer Research Faculty, 2012-2014; and is currently chair of the ESMO Translational Research and Precision Medicine Working Group.
ESMO 2017 Congress
"The Metastatic Breast Cancer Track will address the issue of how to integrate new drugs into the current landscape and which tools are available to facilitate such implementation. The main goal for the scientific committee was to provide the tools to attendees to understand the value of new drugs in mBC and to discuss the potential biomarkers to better select patients."